Company intelligence / Profile preview

UNeMed

Omaha, Nebraska, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

UNeMed facilitates technology transfer and licensing for preclinical-stage technologies in therapeutics and medtech, spanning small molecules, biologics, gene therapies, and drug delivery platforms. Most assets are at the preclinical or proof-of-concept stage, with promising early studies in cancer, osteoarthritis, and other indications[5].

Therapeutic areas: ImmunologyEndocrinologyRheumatologyGastroenterologyInfectious DiseasesRare DiseasesOncology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateGene therapyCell therapymRNA-based drugsProteinNanoparticleRecombinant proteinPeptides
Industry: Drug Discovery Services

Partnerships

University of Nebraska Medical CenterUniversity of Nebraska at OmahaNebraska Medicine

Beyond the preview

Go deeper on UNeMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UNeMed.

Explore the full profile